MMSI

Medical device company Merit Medical Systems (NASDAQ:MMSI) beat Wall Street’s revenue expectations in Q3 2026, with sales up 8.4% year on year to $416.2 million.

Merit Medical Systems reported Q3 2026 revenue of US$416.24 million and net income of US$42.31 million, with management lifting full year guidance and highlighting broad based demand across its product platforms.

Merit Medical Systems has delivered a solid multi year share price run, and recent deal activity is putting fresh focus on whether that performance lines up with the cash the business can generate.

What Merit Medical Systems’ Latest Earnings Tell You Merit Medical Systems (MMSI) just reported third quarter 2026 results, with sales of US$416.24 million and net income of US$42.31 million, both higher than the same period a year earlier.

Although the revenue and EPS for Merit Medical (MMSI) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Merit Medical Systems (NASDAQ:MMSI) reported third-quarter 2026 revenue of $416 million, up 8% year over year on both a GAAP and constant-currency basis, as organic constant-currency growth reached 9% and exceeded management’s prior expectations.

Medical device company Merit Medical Systems (NASDAQ:MMSI) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue rising 8.4% year on year to $416.2 million.

Medical device company Merit Medical Systems (NASDAQ:MMSI) will be reporting earnings this Thursday afternoon. Here’s what investors should know.

Conestoga Capital Advisors, an asset management company, released its third-quarter 2026 investor letter. The letter can be downloaded here.

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including Merit Medical Systems (NASDAQ:MMSI) and its peers.